Cargando…

Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer

SIMPLE SUMMARY: The five-year survival for resectable proximal gastric, gastroesophageal junction (GEJ), and distal esophageal cancer ranges from 30 to 60% globally. Neoadjuvant and/or perioperative therapy has emerged as a treatment tool to improve patient selection for surgery, resectability, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmad, M. Usman, Javadi, Christopher, Poultsides, George A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996907/ https://www.ncbi.nlm.nih.gov/pubmed/35406527 http://dx.doi.org/10.3390/cancers14071755

Ejemplares similares

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
por: Zhu, Jie, et al.
Publicado: (2022)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy
por: Paszt, Attila, et al.
Publicado: (2023)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Higher incidence of gastroesophageal reflux disease after gastric wedge resections of gastric submucosal tumors located close to the gastroesophageal junction
por: Ko, Seung Yeon, et al.
Publicado: (2014)

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
por: Faron, Matthieu, et al.
Publicado: (2023)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

The expressions and prognostic implications of Twist and E-cadherin in adenocarcinomas of the gastroesophageal junction and proximal gastric carcinoma
por: Sun, Shengbo, et al.
Publicado: (2019)

Techniques and short-term outcomes for total minimally invasive Ivor Lewis esophageal resection in distal esophageal and gastroesophageal junction cancers: pooled data from six European centers
por: Straatman, Jennifer, et al.
Publicado: (2016)

Incidence and Dosimetric Predictors of Radiation-Induced Gastric Bleeding After Chemoradiation for Esophageal and Gastroesophageal Junction Cancer
por: Montovano, Margaret, et al.
Publicado: (2021)

Incidence of Microscopically Positive Proximal Margins in Adenocarcinoma of the Gastroesophageal Junction
por: Gao, Fei, et al.
Publicado: (2014)

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study
por: Pape, Marieke, et al.
Publicado: (2023)

Trans-pacific multicenter collaborative study of minimally invasive proximal versus total gastrectomy for proximal gastric and gastroesophageal junction cancers
por: Ikoma, Naruhiko, et al.
Publicado: (2023)

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Laparoscopic Gastric Wedge Resection and Prophylactic Antireflux Surgery for a Submucosal Tumor of Gastroesophageal Junction
por: Lee, Jeong Sun, et al.
Publicado: (2011)

Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population
por: Lago, Nieves Martínez, et al.
Publicado: (2020)

Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers
por: Kastelowitz, Noah, et al.
Publicado: (2021)

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors
por: McGillivray, Erin, et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
por: Zandirad, Eric, et al.
Publicado: (2022)

Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancer
por: Zlotnik, Oran, et al.
Publicado: (2021)

Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
por: Paschold, Lisa, et al.
Publicado: (2022)

Feature Review Papers on Gastroesophageal Junction and Gastric Cancers
por: Gronnier, Caroline
Publicado: (2022)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas
por: Gao, Xianchun, et al.
Publicado: (2021)

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis
por: Yuan, Zhen, et al.
Publicado: (2023)

Trends in surgical techniques for the treatment of esophageal and gastroesophageal junction cancer: the 2022 update
por: de Groot, E M, et al.
Publicado: (2023)

Post-neoadjuvant chemoradiotherapy tumor resectability following induction chemotherapy in locally advanced proximal gastric and adenocarcinoma of the esophagogastric junction: A clinical trial
por: Aledavood, Seyed Amir, et al.
Publicado: (2021)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
por: HUANG, JUN-XING, et al.
Publicado: (2013)

A comparison of neoadjuvant therapies for gastroesophageal and gastric cancer on tumour resection rate: A network meta-analysis
por: Herng, Seow Chee, et al.
Publicado: (2022)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Squamous Cell Carcinoma of the Esophagus and Adenocarcinoma of Gastroesophageal Junction, a Rare Coincidence
por: Geramizadeh, B, et al.
Publicado: (2011)

Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia
por: Jeromen, Ana, et al.
Publicado: (2012)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis
por: Cai, Zhaolun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_osm79largmigau576u5suo76cd